Drug news
NICE to reassess Besponsa for CD 22 positive B cell precursor ALL.- Pfizer.
Following a successful appeal by Pfizer the National Institute for Health and Care Excellence (NICE) will reassess Besponsa (inotuzumab ozogamicin) as a treatment for adults with relapsed or refractory CD 22 positive B cell precursor Acute Lymphoblastic Leukemia. The Institute had considered that the trial evidence offered no survival benefit compared to current treatments.